Findings show inclusion significantly cuts odds of pressure injuries in patients hospitalized with severe COVID-19

Two doses of RZV recommended for adults 19 years and older who are immunocompromised due to disease or therapy

Rates for three largest race and Hispanic-origin groups did not significantly change; increase in rates reported in one state, decline reported in two states

As of Jan. 27, COVID-19 passes will no longer be needed to enter large-scale events, use of face masks in public schools will no longer be required

Monoclonal antibody treatment used infrequently among all racial, ethnic groups; Hispanics received mAbs less often than non-Hispanics

All deformation parameters on echocardiogram recovered within first week, including LV global longitudinal strain, peak left atrial strain

Machine learning model incorporates data from 14 proteins derived from a single blood sample to predict survival in patients with COVID-19

Two doses highly effective against COVID-19-related hospitalization and critical illness for those aged 12 to 18 years

Inability to fulfill elements of decisional capacity coupled with need for rapid treatment decisions complicates consent

Move follows updated mask guidance issued by the CDC late last week